BridgeBio Pharma, Inc.
BBIO
$38.62
$0.280.73%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 1,882.88% | 115.30% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1,882.88% | 115.30% | |||
| Cost of Revenue | 26.63% | 248.49% | |||
| Gross Profit | 2,901.42% | 77.98% | |||
| SG&A Expenses | 12.22% | 37.73% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.98% | 19.67% | |||
| Operating Income | 53.10% | -18.28% | |||
| Income Before Tax | 36.29% | -62.09% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 36.57% | -62.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -6.54% | 5.65% | |||
| Net Income | 36.83% | -63.57% | |||
| EBIT | 53.10% | -18.28% | |||
| EBITDA | 53.39% | -18.52% | |||
| EPS Basic | 37.07% | -62.76% | |||
| Normalized Basic EPS | 44.20% | -23.26% | |||
| EPS Diluted | 37.07% | -62.76% | |||
| Normalized Diluted EPS | 44.20% | -23.26% | |||
| Average Basic Shares Outstanding | 0.37% | 0.49% | |||
| Average Diluted Shares Outstanding | 0.37% | 0.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||